H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... Wedbush analyst Laura Chico maintained a Buy rating on Biohaven ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Shares of Biohaven stock opened at $37.24 on Thursday. The business’s 50 day simple moving average is $38.20 and its two-hundred day simple moving average is $42.75. The stock has a market ...

Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep reductions in total IgG, advancing a novel and transformative ...

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

which made a whopping $37 billion in sales last year to become the top-selling pharmaceutical product worldwide. It's worth noting that Biohaven has just reported that sales of Nurtec ODT came in ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth ...